Online inquiry

IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13570MR)

This product GTTS-WQ13570MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets GPI-APs gene. The antibody can be applied in Benign prostatic hyperplasia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Aeromonas hydrophila
RefSeq NM_000615.7; NM_001144822.2; NM_000591.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684; 965; 929
UniProt ID P13591; P19256; P08571
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13570MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4023MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ10590MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ15028MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ895MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ12630MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ623MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ11894MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ3263MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ART621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW